CJC-1295 (no DAC)

Method detects tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH2, and somatorelin.; LOD of 0.2 ng/mL and LOQ of 0.6 ng/mL achieved.; Linearity established from 0.1 ng/mL to 1.2 ng/mL.; Validated per WADA criteria for selectivity, LOD, carryover, reliability, stability, and recovery.

Magnetic beads with different supports, binding capacities, and affinity chemistries were compared for immunopurification of GHRH analogues from urine.; The immunopurification protocol was optimized using the magnetic beads that provided better recoveries.; The validated method showed intra-day precision below 15% and inter-day precision below 25%.; Limits of detection and identification were 0.2 ng/mL and 0.5 ng/mL, respectively.

Seized powders contained glycine-modified analogs of GHRP-2, GHRP-6, Ipamorelin, and modified GRF 1-29.; Modification involved addition of glycine at the N-terminus in all cases.; Analytical methods for growth hormone secretagogues should be updated to include these variants.

Anabolic androgenic steroids, used for body image and performance enhancement, were the most discussed doping product type.; 327 suppliers were detected, mostly selling via dedicated websites or direct e-mail sales.; Temporal analysis showed stability of popular products alongside the emergence of new substances like peptides (e.g., CJC-1295).; The methodology can detect products and suppliers and track temporal trends, supporting online monitoring, customs inspection, and anti-doping analysis.

Method detected four GHRHs (Sermorelin, CJC-1293, CJC-1295, Tesamorelin) and two metabolites with lower limit of detection <50 pg/mL.; Recovery ranged from 19-37%, with imprecision below 20% and acceptable specificity and linearity.; All intact GHRHs were detected in rat plasma up to 4 hours post-administration, but no anticipated metabolites were found in rats.; A Geref metabolite (GHRH3-29) was identified in a human plasma sample after subcutaneous injection, highlighting species differences.

The preparation contained a 29 amino acid peptide with a C-terminal amide.; The peptide sequence matched CJC-1295, a growth-hormone-releasing factor.; CJC-1295 is listed as a Prohibited Substance under Section S2 of the WADA Prohibited List.; The substance has potential performance-enhancing effects and is available for illicit use.

Two protein spots decreased after treatment: apolipoprotein A1 isoform and transthyretin isoform.; Three protein spots increased after treatment: beta-hemoglobin, a C-terminal albumin fragment, and a mix of immunoglobulin and albumin fragments.; A linear relationship was found between the spot containing immunoglobulin and albumin fragments and IGF-1 levels.; Identified proteins may serve as potential biomarkers for GH and/or IGF-1 activity.

Br-M3-KO mice lacking brain M3 muscarinic receptors show a dwarf phenotype with anterior pituitary hypoplasia; Pituitary and serum growth hormone and prolactin are markedly decreased in these mice; Treatment with the GHRH analog CJC-1295 rescued the growth deficit, restoring normal pituitary size and serum GH and IGF-1 levels; Findings support a model in which central (hypothalamic) M3 receptors are required for proper function of hypothalamic GHRH neurons

What is CJC-1295 (no DAC)?

**Mechanism of Action** CJC-1295 (without DAC) is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) comprising amino acids 1–29. Its structural modifications (e.g., substitution at positions 2, 8, 15, and 27) confer resistance to dipeptidyl peptidase IV (DPP-IV) degradation, extending its h

How does CJC-1295 (no DAC) work?

Tetrasubstituted GHRH(1-29) analog with improved enzymatic stability that amplifies pulsatile GH secretion.

What is the research status of CJC-1295 (no DAC)?

CJC-1295 (no DAC) is currently classified as experimental, with 36 research references on record. This is for research purposes only and is not medical advice.